A Prospective Study of Patients with Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation


About this study

The purpose of this study is to determine the change in health outcomes and cardiac structure and function of subjects with HLHS following successful separation from cardiopulmonary bypass and reversal of anticoagulation at the time of elective Stage II Glenn surgical palliation.




Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Individuals with HLHS having undergone Stage I surgical palliation and undergoing planned Stage II palliative Glenn surgery.
  • Individuals up to 18 months of age are eligible if written informed consent can be obtained from both parents and/or legal guardians, unless one parent is not reasonably available.

Exclusion Criteria:

  • Parent(s)/child unwilling to participate.
  • Child with severe chronic diseases, extensive extra-cardiac syndromic features, or history of cancer.
  • Child has not completed or will not be completing all pre-procedure work-up within 10 days of the Stage II Glenn surgery as listed in section 5 of this protocol AND lack of pre-procedure work-up documented as a safety concern by a site investigator.
  • Child with the following complications of their congenital heart disease:
    • Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage II surgical repair;
    • Severe pulmonary hypertension (reported in the medical record as >70% systemic pressure); and
    • Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome during or after Stage II surgical repair.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Muhammad Qureshi, M.B.B.S.

Closed for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions